Skip Navigation
Skip to contents

Cancer Res Treat : Cancer Research and Treatment

OPEN ACCESS

Search

Page Path
HOME > Search
3 "Moonkyoo Kong"
Filter
Filter
Article category
Keywords
Publication year
Authors
Original Articles
Predictive Factors for Radiation Pneumonitis in Lung Cancer Treated with Helical Tomotherapy
Youngkyong Kim, Seong Eon Hong, Moonkyoo Kong, Jinhyun Choi
Cancer Res Treat. 2013;45(4):295-302.   Published online December 31, 2013
DOI: https://doi.org/10.4143/crt.2013.45.4.295
AbstractAbstract PDFPubReaderePub
PURPOSE
Predictive factors for radiation pneumonitis (RP) after helical tomotherapy (HT) may differ from those after linac-based radiotherapy. In this study, we identified predictive factors for RP in patients with lung cancer treated with HT.
MATERIALS AND METHODS
We retrospectively analyzed clinical, treatment-related and dosimetric factors from 31 patients with lung cancer treated with HT. RP was graded according to Common Terminology Criteria for Adverse Events version 4.0 and grade > or =2 RP was defined as a RP event. We used Kaplan-Meier methods to compute the actuarial incidence of RP. For univariate and multivariate analysis, the log-rank test and the Cox proportional regression hazard model were used. We generated receiver-operating characteristics (ROC) curves to define the cutoff values for significant parameters.
RESULTS
The median follow-up duration was 6.6 months (range, 1.6 to 38.5 months). The 2-, 4-, and 6-month actuarial RP event rates were 13.2%, 58.5%, and 67.0%, respectively. There was no grade 4 or more RP. Ipsilateral V5, V10, V15, and contralateral V5 were related with RP event on univariate analysis. By multivariate analysis, ipsilateral V10 was factor most strongly associated with RP event. On the ROC curve, the cutoff values of ipsilateral V5, V10, V15, and contralateral V5 were 67.5%, 58.5%, 50.0%, and 55.5%, respectively.
CONCLUSION
In our study, ipsilateral V5, V10, V15, and contralateral V5 were significant predictive factors for RP after HT.

Citations

Citations to this article as recorded by  
  • A controlled trial comparing dosimetry and radiation pneumonitis between tomotherapy and IMRT in patients with lung or esophageal cancer
    Anmei Zhang, Yang Zhang, Jingyun Yang, Lu Chen, Na Wu, Jindong Qian, Hongya Dai, Dingqiang Yang, Lirong Zhao, Liangzhi Zhong, Tianxiang Cui, Fan Yang, Guangpeng Chen, Yixing Gao, Wen Luo, Guanghui Li
    Journal of Applied Clinical Medical Physics.2026;[Epub]     CrossRef
  • Predictive factors for severe radiation-induced lung injury in patients with lung cancer and coexisting interstitial lung disease
    Shin-Hyung Park, Jae-Kwang Lim, Min Kyu Kang, Jongmoo Park, Chae Moon Hong, Chang Ho Kim, Seung Ick Cha, Jaehee Lee, Seoung-Jun Lee, Jae-Chul Kim
    Radiotherapy and Oncology.2024; 192: 110053.     CrossRef
  • Deep-Learning Model Prediction of Radiation Pneumonitis Using Pretreatment Chest Computed Tomography and Clinical Factors
    Jang Hyung Lee, Min Kyu Kang, Jongmoo Park, Seoung-Jun Lee, Jae-Chul Kim, Shin-Hyung Park
    Technology in Cancer Research & Treatment.2024;[Epub]     CrossRef
  • Pulmonary toxicity of craniospinal irradiation using helical tomotherapy
    Joongyo Lee, Euidam Kim, Nalee Kim, Chang-Ok Suh, Yoonsun Chung, Hong In Yoon
    Scientific Reports.2022;[Epub]     CrossRef
  • Comparison of Radiation Pneumonitis in Lung Cancer Patients Treated with HT versus IMRT and Circulating Lymphocyte Subsets as Predicting Risk Factors
    Xin Zhang, Dingyi Yang, Yong Jiang, Luo Huang, Can Wang, Dan Tao, Xianfeng Liu, Yongyang Lei, Yongzhong Wu, Wei Zhou
    Journal of Inflammation Research.2021; Volume 14: 4205.     CrossRef
  • The Efficacy and Safety of Acupuncture for Preventing Radiation Pneumonitis in Patients With Lung Cancer: A Prospective, Single-Blinded, Randomized Pilot Proof-of-Principle Study
    Moonkyoo Kong, Seung Hyeun Lee, Jaehyo Kim, Beom-Joon Lee, Kwan-Il Kim
    Integrative Cancer Therapies.2020;[Epub]     CrossRef
  • Phase II study of compensator-based non-coplanar intensity-modulated radiotherapy for Stage I non–small-cell lung cancer
    Tomohiro Itonaga, Ryuji Mikami, Hidetsugu Nakayama, Tatsuhiko Saito, Sachika Shiraishi, Mitsuru Okubo, Shinji Sugahara, Norihiko Ikeda, Koichi Tokuuye
    Journal of Radiation Research.2019; 60(3): 387.     CrossRef
  • Dosimetric Comparison Between Jaw Tracking and No Jaw Tracking in Intensity-Modulated Radiation Therapy
    Shengyu Yao, Yin Zhang, Tingfeng Chen, Guoqi Zhao, Zhekai Hu, Xiaokai Lu, Yong Liu
    Technology in Cancer Research & Treatment.2019;[Epub]     CrossRef
  • A new Monte Carlo model of a Cyberknife® system for the precise determination of out-of-field doses
    J Colnot, V Barraux, C Loiseau, P Berejny, A Batalla, R Gschwind, C Huet
    Physics in Medicine & Biology.2019; 64(19): 195008.     CrossRef
  • Treatment outcomes and patterns of radiologic appearance after hypofractionated image-guided radiotherapy delivered with helical tomotherapy (HHT) for lung tumours
    Stefano Arcangeli, Lorenzo Falcinelli, Stefano Bracci, Alessandro Greco, Alessia Monaco, Jessica Dognini, Cinzia Chiostrini, Rita Bellavita, Cynthia Aristei, Vittorio Donato
    The British Journal of Radiology.2017;[Epub]     CrossRef
  • Patterns of CT lung injury and toxicity after stereotactic radiotherapy delivered with helical tomotherapy in early stage medically inoperable NSCLC
    S Arcangeli, L Agolli, L Portalone, M R Migliorino, M G Lopergolo, A Monaco, J Dognini, M C Pressello, S Bracci, V Donato
    The British Journal of Radiology.2015; 88(1048): 20140728.     CrossRef
  • Early Toxicity in Patients Treated With Postoperative Proton Therapy for Locally Advanced Breast Cancer
    John J. Cuaron, Brian Chon, Henry Tsai, Anuj Goenka, David DeBlois, Alice Ho, Simon Powell, Eugen Hug, Oren Cahlon
    International Journal of Radiation Oncology*Biology*Physics.2015; 92(2): 284.     CrossRef
  • Risk of radiation-induced pneumonitis after helical and static-port tomotherapy in lung cancer patients and experimental rats
    Xianglan Zhang, You Keun Shin, Zhenlong Zheng, Lianhua Zhu, Ik Jae Lee
    Radiation Oncology.2015;[Epub]     CrossRef
  • Dosimetric Comparisons of Lung SBRT with Multiple Metastases by Two Advanced Planning Systems
    Ye Zhang, Yie Chen, Jie Qiu, Jack Yang
    International Journal of Medical Physics, Clinical Engineering and Radiation Oncology.2014; 03(04): 252.     CrossRef
  • Frameless stereotactic body radiation therapy for multiple lung metastases
    Qilin Li, Jinming Mu, Wendong Gu, Yuan Chen, Zhonghua Ning, Jianxue Jin, Honglei Pei
    Journal of Applied Clinical Medical Physics.2014; 15(4): 105.     CrossRef
  • 15,285 View
  • 73 Download
  • 15 Crossref
Close layer
Which Patients Might Benefit from Postmastectomy Radiotherapy in Breast Cancer Patients with T1-2 Tumor and 1-3 Axillary Lymph Nodes Metastasis?
Moonkyoo Kong, Seong Eon Hong
Cancer Res Treat. 2013;45(2):103-111.   Published online June 30, 2013
DOI: https://doi.org/10.4143/crt.2013.45.2.103
AbstractAbstract PDFPubReaderePub
PURPOSE
This study compared the clinical outcomes of T1-2N1 breast cancer patients with and without postmastectomy radiotherapy (PMRT). Risk factors for loco-regional recurrence (LRR) were identified in order to define a subgroup of patients who might benefit from PMRT.
MATERIALS AND METHODS
Of 110 T1-2N1 breast cancer patients who underwent mastectomy from January 1994 through December 2009, 32 patients underwent PMRT and 78 patients did not. Treatment outcomes and risk factors for LRR were analyzed.
RESULTS
The 5- and 10-year LRR rates were both 6.2% in the PMRT group, and 10.4% and 14.6% in the no-PMRT group (p=0.336). In addition, no significant differences in distant metastasis-free survival (DMFS) or overall survival (OS) were observed between patients receiving and not receiving PMRT. In multivariate analysis, factors associated with higher LRR rates included grade 3 disease, extracapsular extension (ECE), and triple negative subtype. Patients who had one or more risk factors for LRR were defined as a high-risk patient group. In the high-risk group, both 5- and 10-year LRR rates for patients who underwent PMRT was 18.2%, and LRR rates of 21.4% at five years and 36.6% at 10 years were observed for patients who did not undergo PMRT (p=0.069).
CONCLUSION
PMRT in T1-2N1 breast cancer patients should be considered according to several prognostic factors in addition to T and N stage. Findings of our study indicated that PMRT did not improve LRR, DMFS, or OS in T1-2N1 breast cancer patients. However, in a subgroup of patients with grade 3 disease, ECE, or triple negative subtype, PMRT might be beneficial.

Citations

Citations to this article as recorded by  
  • Postmastectomy radiation therapy for patients with pT1-2N1 breast cancer over 2 decades in Korea: Korean Radiation Oncology Group 14-21
    Mi Sun Kim, Seung Do Ahn, Yong Bae Kim, Won Park, Shin-Hyung Park, Ik Jae Lee, Byung-Ock Choi, Juri Kim, Sung Ja Ahn, Won Sup Yoon, Jin-hee Kim, Jong Hoon Lee, Donghyun Kim, Hye Li Park, Yeon-Joo Kim, Sun Young Lee, Kyung Ran Park
    Radiation Oncology Journal.2025; 43(4): 172.     CrossRef
  • A Prognostic Risk Stratification Model to Identify Potential Population Benefiting From Postmastectomy Radiotherapy in T1–2 Breast Cancer With 1–3 Positive Axillary Lymph Nodes
    Niuniu Hou, Juliang Zhang, Lu Yang, Ying Wu, Zhe Wang, Mingkun Zhang, Li Yang, Guangdong Hou, Jianfeng Wu, Yidi Wang, Bingyao Dong, Lili Guo, Mei Shi, Rui Ling
    Frontiers in Oncology.2021;[Epub]     CrossRef
  • SKIN AND SUBCUTANEOUS ADIPOSE TISSUE DAMAGE AFTER RADIATION THERAPY IN BREAST CANCER PATIENTS
    D. Bazyka, O. Litvinenko, S. Bugaytsov, G. Shakhrai
    Проблеми радіаційної медицини та радіобіології = Problems of Radiation Medicine and Radiobiology.2021; 26: 18.     CrossRef
  • Multidisciplinary Management of the Axilla in Patients with cT1-T2 N0 Breast Cancer Undergoing Primary Mastectomy: Results from a Prospective Single-Institution Series
    Samantha Grossmith, Anvy Nguyen, Jiani Hu, Jennifer K. Plichta, Faina Nakhlis, Linda Cutone, Laura Dominici, Mehra Golshan, Margaret Duggan, Katharine Carter, Esther Rhei, Thanh Barbie, Katherina Calvillo, Suniti Nimbkar, Jennifer Bellon, Julia Wong, Rina
    Annals of Surgical Oncology.2018; 25(12): 3527.     CrossRef
  • A prognostic score model to determine which breast cancer patients with 1-3 positive lymph nodes after modified radical mastectomy should receive radiotherapy
    Dawei Chen, Haiyong Wang, Xinyu Song, Fang Shi, Li Kong, Jinming Yu
    Oncotarget.2018; 9(1): 385.     CrossRef
  • Postmastectomy radiation therapy for breast cancer patients with one to three positive lymph nodes: a propensity score matching analysis
    Jiamao Lin, Cheng Li, Chenyue Zhang, Fang Shi, Haiyong Wang
    Future Oncology.2017; 13(16): 1395.     CrossRef
  • Predicting loco-regional recurrence risk in T1, T2 breast cancer with 1–3 positive axillary nodes postmastectomy: Development of a predictive nomogram
    T Wadasadawala, S Kannan, S Gudi, A Rishi, A Budrukkar, V Parmar, T Shet, S Desai, S Gupta, R Badwe, R Sarin
    Indian Journal of Cancer.2017; 54(1): 352.     CrossRef
  • Comparison of Treatment Outcomes between Breast Conserving Surgery Followed by Radiotherapy and Mastectomy Alone in Patients with T1-2 Stage and 1-3 Axillary Lymph Nodes in the Era of Modern Adjuvant Systemic Treatments
    Sang-Won Kim, Mison Chun, Sehwan Han, Yong Sik Jung, Jin Hyuk Choi, Seok Yun Kang, Hyunsoo Jang, Sunmi Jo, William B. Coleman
    PLOS ONE.2016; 11(9): e0163748.     CrossRef
  • Improvement of survival with postmastectomy radiotherapy in patients with 1-3 positive axillary lymph nodes: A systematic review and meta-analysis of the current literature
    Hannah Headon, Abdul Kasem, Reham Almukbel, Kefah Mokbel
    Molecular and Clinical Oncology.2016; 5(4): 429.     CrossRef
  • ABCB1polymorphism as prognostic factor in breast cancer patients treated with docetaxel and doxorubicin neoadjuvant chemotherapy
    Hee‐Jun Kim, Seock‐Ah Im, Bhumsuk Keam, Hye Seon Ham, Kyung Hun Lee, Tae Yong Kim, Yu Jung Kim, Do‐Youn Oh, Jee Hyun Kim, Wonshik Han, In‐Jin Jang, Tae‐You Kim, In Ae Park, Dong Young Noh
    Cancer Science.2015; 106(1): 86.     CrossRef
  • Conservative Axillary Surgery in Breast Cancer Patients Undergoing Mastectomy: Long-Term Results
    Michael S. Cowher, Stephen R. Grobmyer, Joanne Lyons, Colin O'Rourke, Deborah Baynes, Joseph P. Crowe
    Journal of the American College of Surgeons.2014; 218(4): 819.     CrossRef
  • 11,946 View
  • 65 Download
  • 11 Crossref
Close layer
Preoperative Concurrent Chemoradiotherapy for Locally Advanced Rectal Cancer: Treatment Outcomes and Analysis of Prognostic Factors
Moonkyoo Kong, Seong Eon Hong, Woo Suk Choi, Si-Young Kim, Jinhyun Choi
Cancer Res Treat. 2012;44(2):104-112.   Published online June 30, 2012
DOI: https://doi.org/10.4143/crt.2012.44.2.104
AbstractAbstract PDFPubReaderePub
PURPOSE
This study was designed to investigate the long-term oncologic outcomes for locally advanced rectal cancer patients after treatment with preoperative concurrent chemoradiotherapy followed by total mesorectal excision, and to identify prognostic factors that affect survival and pathologic response.
MATERIALS AND METHODS
From June 1996 to June 2009, 135 patients with locally advanced rectal cancer were treated with preoperative concurrent chemoradiotherapy followed by total mesorectal excision at Kyung Hee University Hospital. Patient data was retrospectively collected and analyzed in order to determine the treatment outcomes and identify prognostic factors for survival.
RESULTS
The median follow-up time was 50 months (range, 4.5 to 157.8 months). After preoperative chemoradiotherapy, sphincter preservation surgery was accomplished in 67.4% of whole patients. A complete pathologic response was achieved in 16% of patients. The estimated 5- and 8-year overall survival, loco-regional recurrence-free survival, and distant metastasis-free survival rate for all patients was 82.7% and 75.7%, 76.8% and 71.9%, 67.9% and 63.3%, respectively. The estimated 5- and 8-year overall survival, loco-regional recurrence-free survival, and distant metastasis-free survival rate for pathologic complete responders was 100% and 100%, 100% and 88.9%, 95.5% and 95.5%, respectively. In the multivariate analysis, pathologic complete response was significantly associated with overall survival. The predictive factor for pathologic complete response was pretreatment clinical stage.
CONCLUSION
Preoperative chemoradiotherapy for locally advanced rectal cancer resulted in a high rate of overall survival, sphincter preservation, down-staging, and pathologic complete response. The patients achieving pathologic complete response had very favorable outcomes. Pathologic complete response was a significant prognostic factor for overall survival and the significant predictive factor for a pathologic complete response was pretreatment clinical stage.

Citations

Citations to this article as recorded by  
  • Analysis of clinical and pathological prognostic factors of survival in rectal adenocarcinoma treated with preoperative radiochemotherapy
    Sarhan Sydney Saad, Nora Forones, Gaspar Lopes Filho, Jaques Waisberg, Elesiario Caetano Júnior, Ricardo Artigiani-Neto, Delcio Matos
    Acta Cirúrgica Brasileira.2025;[Epub]     CrossRef
  • The optimal time interval between neoadjuvant chemoradiotherapy and surgery for patients with an unfavorable pathological response in locally advanced rectal cancer: a retrospective cohort study
    Litao Wang, Jianyong Fan, Yaqi Guo, Shipeng Shang, Han Gao, Jianfei Xu, Peng Gao, Enrui Liu
    Frontiers in Oncology.2025;[Epub]     CrossRef
  • Characteristics of Patients Presented With Metastases During or After Completion of Chemoradiation Therapy for Locally Advanced Rectal Cancer: A Case Series
    Radwan Torky, Mohammed Alessa, Ho Seung Kim, Ahmed Sakr, Eman Zakarneh, Fozan Sauri, Heejin Bae, Nam Kyu Kim
    Annals of Coloproctology.2021; 37(3): 186.     CrossRef
  • A prospective analysis of the diagnostic accuracy of 3 T MRI, CT and endoscopic ultrasound for preoperative T staging of potentially resectable esophageal cancer
    Jia Guo, Zhaoqi Wang, Jianjun Qin, Hongkai Zhang, Wentao Liu, Yan Zhao, Yanan Lu, Xu Yan, Zhongxian Zhang, Ting Zhang, Shouning Zhang, Nickel Marcel Dominik, Ihab R. Kamel, Hailiang Li, Jinrong Qu
    Cancer Imaging.2020;[Epub]     CrossRef
  • Sustaining Blood Lymphocyte Count during Preoperative Chemoradiotherapy as a Predictive Marker for Pathologic Complete Response in Locally Advanced Rectal Cancer
    Jaesung Heo, Mison Chun, O Kyu Noh, Young-Taek Oh, Kwang Wook Suh, Jun Eun Park, Oyeon Cho
    Cancer Research and Treatment.2016; 48(1): 232.     CrossRef
  • Differential effects of patient-related factors on the outcome of radiation therapy for rectal cancer
    Ikuko Kato, Gregory Dyson, Michael Snyder, Hyeong-Reh Kim, Richard K. Severson
    Journal of Radiation Oncology.2016; 5(3): 279.     CrossRef
  • JOURNAL CLUB: Preoperative MRI Evaluation of Primary Rectal Cancer: Intrasubject Comparison With and Without Rectal Distention
    Feng Ye, Hongmei Zhang, Xiao Liang, Han Ouyang, Xinming Zhao, Chunwu Zhou
    American Journal of Roentgenology.2016; 207(1): 32.     CrossRef
  • Utility of high resolution MRI for pre-operative staging of rectal carcinoma, involvement of the mesorectal fascia and circumferential resection margin
    Tamir A. Hassan, Hossam M. Abdel-Rahman, Hala Yehia Ali
    The Egyptian Journal of Radiology and Nuclear Medicine.2016; 47(4): 1243.     CrossRef
  • Severe weight loss during preoperative chemoradiotherapy compromises survival outcome for patients with locally advanced rectal cancer
    Junzhong Lin, Jianhong Peng, Aiham Qdaisat, Liren Li, Gong Chen, Zhenhai Lu, Xiaojun Wu, Yuanhong Gao, Zhifan Zeng, Peirong Ding, Zhizhong Pan
    Journal of Cancer Research and Clinical Oncology.2016; 142(12): 2551.     CrossRef
  • Complete radiotherapy response in rectal cancer: A review of the evidence
    Daniel G Couch
    World Journal of Gastroenterology.2016; 22(2): 467.     CrossRef
  • The Value of High-Resolution MRI Technique in Patients with Rectal Carcinoma: Pre-Operative Assessment of Mesorectal Fascia Involvement, Circumferential Resection Margin and Local Staging
    Samah Kohla
    Polish Journal of Radiology.2015; 80: 115.     CrossRef
  • Is complete mesocolic excision with central vascular ligation safe and effective in the surgical treatment of right-sided colon cancers? A prospective study
    Gennaro Galizia, Eva Lieto, Ferdinando De Vita, Francesca Ferraraccio, Anna Zamboli, Andrea Mabilia, Annamaria Auricchio, Paolo Castellano, Vincenzo Napolitano, Michele Orditura
    International Journal of Colorectal Disease.2014; 29(1): 89.     CrossRef
  • Accuracy of High-Resolution MRI with Lumen Distention in Rectal Cancer Staging and Circumferential Margin Involvement Prediction
    Elsa Iannicelli, Sara Di Renzo, Mario Ferri, Emanuela Pilozzi, Marco Di Girolamo, Alessandra Sapori, Vincenzo Ziparo, Vincenzo David
    Korean Journal of Radiology.2014; 15(1): 37.     CrossRef
  • EURECCA colorectal: Multidisciplinary management: European consensus conference colon & rectum
    Cornelis J.H. van de Velde, Petra G. Boelens, Josep M. Borras, Jan-Willem Coebergh, Andres Cervantes, Lennart Blomqvist, Regina G.H. Beets-Tan, Colette B.M. van den Broek, Gina Brown, Eric Van Cutsem, Eloy Espin, Karin Haustermans, Bengt Glimelius, Lene H
    European Journal of Cancer.2014; 50(1): 1.e1.     CrossRef
  • Eine intensivierte Chemotherapie erhöht die Effektivität nicht, oder doch?
    Gunther Klautke
    Info Onkologie.2014; 17(6): 17.     CrossRef
  • Sphincter preservation in distal CT2N0 rectal cancer after preoperative chemoradiotherapy
    Nir Wasserberg, Yulia Kundel, Ofer Purim, Andrei Keidar, Hanoch Kashtan, Eran Sadot, Eyal Fenig, Baruch Brenner
    Radiation Oncology.2014;[Epub]     CrossRef
  • Metformin use and improved response to therapy in rectal cancer
    Heath D. Skinner, Christopher H. Crane, Christopher R. Garrett, Cathy Eng, George J. Chang, John M. Skibber, Miguel A. Rodriguez‐Bigas, Patrick Kelly, Vlad C. Sandulache, Marc E. Delclos, Sunil Krishnan, Prajnan Das
    Cancer Medicine.2013; 2(1): 99.     CrossRef
  • 14,740 View
  • 55 Download
  • 17 Crossref
Close layer

Cancer Res Treat : Cancer Research and Treatment
Close layer
TOP